Literature DB >> 8397002

Anti-infectivity activity of human salivary secretions toward human immunodeficiency virus.

M R Robinovitch1, J M Iversen, L Resnick.   

Abstract

The purpose of this investigation was to adapt an MT-2 cell syncytium-forming assay for measuring anti-infectivity activity of salivary secretions toward HIV and to determine the distribution of this activity in a population of healthy adult subjects. Whole saliva samples were collected from 27 volunteers, who reported that they did not belong to any group at high risk for HIV infection, and tested for anti-infectivity activity using the syncytium-forming assay. Nine of these subjects were subsequently retested on one or more occasions to assess the variability in appearance of this activity. Parotid and extraparotid salivas of six subjects were also tested. Samples were frozen immediately after collection and submitted in blinded fashion for quantitation of their anti-HIV activity using a syncytia-forming MT-2 cell assay or the p24 antigen ELISA. Nine out of the 27 subjects showed detectable anti-HIV infectivity activity. One parotid sample and one extraparotid sample out of four from subjects with positive whole salivas were positive and none of the parotid or extraparotid samples from two subjects with negative whole salivas were positive. The inhibitory activity ranged from 0.5 to 1 log 10 TCID50/ml and could not be correlated with total protein content in saliva or any specific electrophoretic component. Filtration of the saliva through an Amicon 10 filter before incubation with the virus abolished the activity. Similar studies using two other biological fluids, urine and cerebrospinal fluid, revealed no anti-HIV infectivity activity. These findings confirm the presence in saliva of inhibitory activity directed toward HIV.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8397002     DOI: 10.1177/10454411930040032801

Source DB:  PubMed          Journal:  Crit Rev Oral Biol Med        ISSN: 1045-4411


  8 in total

Review 1.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

2.  Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.

Authors:  A A Baqui; T F Meiller; W A Falkler
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

3.  Human immunodeficiency virus type 1 infection and replication in normal human oral keratinocytes.

Authors:  Xuan Liu; Junli Zha; Hongying Chen; Junko Nishitani; Paulo Camargo; Steve W Cole; Jerome A Zack
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 4.  The oral mucosa immune environment and oral transmission of HIV/SIV.

Authors:  Lianna F Wood; Ann Chahroudi; Hui-Ling Chen; Heather B Jaspan; Donald L Sodora
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

5.  Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.

Authors:  T B McNeely; M Dealy; D J Dripps; J M Orenstein; S P Eisenberg; S M Wahl
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 6.  Innate antiviral defenses in body fluids and tissues.

Authors:  S Baron; I Singh; A Chopra; D Coppenhaver; J Pan
Journal:  Antiviral Res       Date:  2000-11       Impact factor: 5.970

7.  Effects of the common cold and intranasal fluticasone propionate treatment on mucosal host defense assessed by human saliva.

Authors:  M Lenander-Lumikari; T Puhakka; M J Mäkelä; P Vilja; O Ruuskanen; J Tenovuo
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1999-06

Review 8.  Mucus and Mucins: do they have a role in the inhibition of the human immunodeficiency virus?

Authors:  Anwar Suleman Mall; Habtom Habte; Yolanda Mthembu; Julia Peacocke; Corena de Beer
Journal:  Virol J       Date:  2017-10-06       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.